Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma.

Glaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are considered a first-line treatment in the management of glaucoma and have the best efficacy in reducing intraocular pressure. When comparing these therapeutic agents between them, long-term therapy with 0.03% bimatoprost is the most effective followed by treatment with 0.005% latanoprost and 0.004% travoprost. The prevalence of adverse events is lower for latanoprost than for other prostaglandin analogs. However, some patients do not respond to the treatment with prostaglandin analogs (non-responders). Intraocular pressure-lowering efficacy differs significantly between individuals partly owing to genetic factors. Rs1045642 in ABCB1, rs4241366 in SLCO2A1, rs9503012 in GMDS, rs10306114 in PTGS1, rs11568658 in MRP4, rs10786455 and rs6686438 in PTGFR were reported to be positive with the response to prostaglandin analogs in patients with glaucoma. A negative association was found between single nucleotide polymorphisms of PTGFR (rs11578155 and rs6672484) and the response to prostaglandin analogs in patients with glaucoma. The current review is an analysis of the information relevant to prostaglandin analog treatments based on previous literatures. It describes in detail the clinical pharmacology and pharmacogenetics of drugs belonging to this therapeutical class to provide a sound pharmacological basis for their proper use in ophthalmological clinical practice.

Detection of dopamine on a mercapto-terminated hexanuclear Fe(III) cluster modified gold electrode.

In this study, a novel mercapto-terminated hexanuclear iron(III) cluster [Fe6O2(OH)2(O2CC6H4SCH3)10(hep)2]·CH3CN·CH2Cl2 [hep=2-(2-hydroxyethyl) pyridine] (Fe6) modified Au electrode was fabricated, having highly sensitive dopamine (DA) detection capabilities. In such Fe6 molecules, 10 thiomethyl groups are located at the periphery of the cluster, which enable the Fe6 molecules to self-assemble onto the surface of Au electrodes through the formation of Au-S bonds. The as-prepared Fe6-modified Au electrode (Au/Fe6) exhibits excellent electrocatalytic activity for the oxidation of dopamine (DA) in PBS with a diffusion coefficient of 3.12×10(-5) cm(2)/s. Using the square wave voltammetry (SWV) technique, the calibration curve for DA determination was obtained in the range of 0.2 to 30 µM, and the detection limit for DA was ~0.07 µM. Furthermore, the modified electrode can accurately separate the DA signal from the interfering effect of uric acid (UA), thus providing simultaneous detection of DA and UA in their binary mixtures. This electrode can be reliably used to assay DA in its real drug composition.